| Methods |
Allocation: randomised.
Blindness: not stated.
Duration: five weeks.
Setting: not reported. |
| Participants |
Diagnosis: schizophrenia (CCMD‐2R).
N=62.
Sex: 35 F, 27 M.
Age: mean 32 yrs.
History: illness 10 yrs (SD 8), ESR (male 0˜15 mm/hour; female 0˜20 mm/hour), WBC: 4*109/L˜10*109/L. |
| Interventions |
1. Clozapine: dose 225 to 500 mg/day. N=32.
2. Chlorpromazine: dose 400 to 700 mg/day. N=30. |
| Outcomes |
Clinical tests: ESR, WBC. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Randomised ‐ no further details |
| Allocation concealment? |
Unclear risk |
No details |
| Blinding?
All outcomes |
Unclear risk |
No details |
| Incomplete outcome data addressed?
All outcomes |
Unclear risk |
No details |
| Free of selective reporting? |
High risk |
Only raised white blood cells reported |
| Free of other bias? |
Unclear risk |
Unclear |
